Solid Malignancies Clinical Trial
Official title:
A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
The purpose of this study is to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer. Patients may receive durvalumab alone or in combination with tremelimumab.
The researchers doing this study are also interested in looking for markers that will help predict which patients are most likely to be helped by the study drugs, durvalumab and tremelimumab. This is done by starting at a dose lower than the one that does not cause side effects in animals. Participants are given durvalumab alone or durvalumab together with tremelimumab and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of durvalumab together with tremelimumab. Participants joining this study later on will get higher doses of durvalumab together with tremelimumab than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The second purpose is to see if there are any differences in the side effects and the way durvalumab and tremelimumab are handled in your body when durvalumab is given together at the same time with tremelimumab compared to when durvalumab is given after tremelimumab. This is called dose level five. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01202370 -
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00162136 -
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
|
Phase 1 | |
| Recruiting |
NCT05006794 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01540526 -
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
|
Phase 1 | |
| Completed |
NCT00033202 -
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
| Completed |
NCT05866354 -
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
|
Phase 1 | |
| Completed |
NCT02640755 -
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
|
Phase 1 | |
| Terminated |
NCT00695370 -
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
|
Phase 2 | |
| Completed |
NCT02325739 -
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
|
Phase 1/Phase 2 | |
| Completed |
NCT00676299 -
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
|
Phase 1 | |
| Active, not recruiting |
NCT00090727 -
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT01112397 -
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT00751894 -
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
|
Phase 2 |